Preparation and Cytotoxicity Effect of Anti-Hepatocellular Carcinoma Scfv Immunoliposome on Hepatocarcinoma Cell in Vitro

European Journal of Inflammation

Article

Y-F. Liu¹  G-H. Zhang²  H-Y. Hu³ 

[1] Department of Patholgy, the Fourth Military Medical University, Xi'an, Shaanxi;Dr Gui-hong Zhang, School of Nursing, the Fourth Military Medical University, 169 ChangLe Road, Xi'an, Shaanxi, 7 10032, P.R.China, Tel: ++029 84774893 Fax: ++029 87854391, e-mail: ;School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, PR. China;

关键词: immunoliposome;    PE38;    immunotoxin;    cytotoxicity;   

DOI  :  10.1177/1721727X1000800204

 received in 2009-09-15, accepted in 2010-04-28,  发布年份 2010

来源: Sage Journals

【 摘 要 】

The use of PE38 for cancer therapy has attracted considerable attention for a long time. However, the extensive use of PE38 is prohibited by its severe side effects. Even though immunotoxin PE38 has been researched for cancer therapy, it has displayed low antitumor activity. The aim of this study is to compare the killing efficacy on Hepatocellular carcinoma (HCC) SMMC-7721 cell of immunoliposome PE38, immunotoxin PE38 and liposome PE38. In this study, the sterically stabilized liposomal PE38 was prepared using soybean phosphatidylcholine, cholesterol, and Cholesterol-PEG-COOH. The humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) was coupled to sterically stabilized liposomes using the N-hydroxysuccinimide ester method. The immunoliposome PE38 was prepared in our lab using the above-mentioned single-chain antibody. The hdsFv25-immunoliposomes were immunoreactive as determined by ELISA assay. Immunoliposome PE38 can kill SMMC-7721 cells in vitro with higher efficiency than non-targeted liposomes. These results indicate that immunoliposome PE38 may be potential in the treatment of hepatocarcinoma.

【 授权许可】

Unknown   
© 2010 SAGE Publications